6533b7d8fe1ef96bd126ae19

RESEARCH PRODUCT

Additional file 3: of A two-gene epigenetic signature for the prediction of response to neoadjuvant chemotherapy in triple-negative breast cancer patients

Begoña PinedaAngel Diaz-lagaresJosé Pérez-fidalgoOctavio BurguésInés González-barralloAna CrujeirasJuan SandovalManel EstellerAna LluchPilar Eroles

subject

description

Eleven differentially methylated CpGs, corresponding to 11 genes, showed significant methylation differences between non-responder and responder patients: 6 genes (LOC641518; LEF1; HOXA5; EVC2; CDKL2; TLX3) presented a methylation increase in non-responders group vs responders, and 5 genes (ZFHX4; LOC100192378; FERD3L; CHL1; TRIP10) decreased methylation level in non-responder patients compared to those who responded to NAC treatment (PPT 225 kb)

https://dx.doi.org/10.6084/m9.figshare.7750505.v1